Modality
Bispecific Ab
MOA
JAK1/2i
Target
PD-1
Pathway
RNA Splicing
ObesityUC
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
~Nov 2017
→ ~Feb 2019
NDA/BLA
May 2019
→ Jan 2027
NDA/BLACurrent
NCT04176619
765 pts·UC
2025-05→2027-01·Completed
NCT08912373
2,390 pts·UC
2019-05→2026-05·Not yet recruiting
3,155 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-051mo awayPh3 Readout· UC
2027-01-2610mo awayPh3 Readout· UC
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
NDA/BLA
Not yet…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2026-05-05 · 1mo away
UC
Ph3 Readout
2027-01-26 · 10mo away
UC
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04176619 | NDA/BLA | UC | Completed | 765 | FEV1 |
| NCT08912373 | NDA/BLA | UC | Not yet recr... | 2390 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |